TIRZEPATIDE 10 mg

Tirzepatide is a novel, synthetic peptide that acts as a dual agonist for GIP and GLP-1 receptors, approved to treat type 2 diabetes and obesity by improving blood sugar control and inducing significant weight loss (up to 20%+ body weight). Administered weekly by injection, it enhances satiety and slows gastric emptying, often proving more effective than selective GLP-1 agonists like semaglutide.

National Institutes of Health (.gov) +5

Key Aspects of Tirzepatide:

• Mechanism: As a "twincretin," it mimics both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

• Approval & Use: FDA-approved (Mounjaro for T2D, Zepbound for weight management) to manage Type 2 Diabetes (T2DM) and obesity

  .

• Efficacy: Trials showed up to a 2.34% reduction in HbA1c and significant, dose-dependent weight loss (15–21% mean reduction).

• Administration: Once-weekly subcutaneous injection.

• Side Effects: Common, usually mild-to-moderate gastrointestinal issues include nausea, diarrhea, vomiting, and constipation, especially during dose escalation and with poor diet.